DEL MAR, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Genece Health, a molecular testing company focused on improving cancer detection for lung, breast, ovarian and other cancers, today announced that Marra Francis, MD, FACOG, has joined the company as its chief medical officer.

Dr. Francis is a board-certified Obstetrician and Gynecologist with over 23 years of clinical practice and 18 years of commercial leadership roles across the diagnostics and biotech sectors. She is also currently a member of the MIT Catalyst Faculty. Most recently, Dr. Francis was an advisor to Droplet Biosciences and to Exai Bio, where she built their respective target product profiles ahead of Droplet’s first product launch and Exai’s clinical validation study. At Delphi, she led an early access program for their flagship commercial test. Dr. Francis’ past experience also includes serving as head of medical affairs for women's health of Sema4 (now GeneDx); as executive medical director of EverlyWell; and as chief medical officer of Aspira Women's Health. Earlier in her career, she served as both vice chair and chair of the Department of Obstetrics and Gynecology at Memorial Hermann Hospital of the Woodlands. Dr. Francis holds a medical degree from the University of Connecticut Health Center and a bachelor of arts degree in biology from Occidental College.

Dr. Marra Francis named as Genece Health CMO

“We are delighted to have Marra join our team at a very exciting time for Genece,” said Greg Gosch, CEO of Genece Heath. “Marra’s clinical expertise in women’s health and oncology will be pivotal in the advancement of our clinical studies and bringing our liquid biopsy and deep-learning AI technology to market. Our goal is to empower physicians with critical insights they need to make informed decisions and improve patient care. Marra will be instrumental in driving key milestones to ultimately help change the way cancer is detected.”

About Genece Health
Genece leverages a proprietary liquid biopsy and deep-learning AI technology for early cancer detection. The Company was founded in 2022 through a strategic partnership with GC Genome, the genomics arm of GC Corporation, a leading life sciences company in South Korea. Genece focuses on the acute need for targeted screening and detection tools to support decision-making when a mass or lump is detected through imaging, empowering physicians to make informed decisions and improve care. The Company’s initial applications include high-mortality and women’s health cancers. For more information, visit genecehealth.com or follow Genece on LinkedIn.

Investor Contact:
investors@genecehealth.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7c648163-47e0-4823-b27d-e8426f22ed15

DEL MAR, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Genece Health, a molecular testing company focused on improving cancer screening for lung, breast, ovarian and other cancers, today announced that four abstracts demonstrating their deep-learning AI and liquid biopsy technology’s performance were selected for presentation at the upcoming 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA. This will be the first time performance data from the company will be shared publicly.

The abstracts will be available on the AACR website and poster presentation details can be found below.

Subject: Lung cancer test results show high sensitivity and specificity
     Title: A Novel Liquid Biopsy Lung Cancer Detection Method Using a Coverage and Fragment End Motif Machine Learning Analysis
     Session Title: Risk Prediction Modeling, Screening, Early Detection, and Preneoplastic and Tumor Markers
     Location: Poster Section 33 Board 3
     Abstract Number: 3448
     Date/Time: Monday April 8, 1:30PM to 5:00PM
     Presenting Author: Bryan Leatham

Subject: A powerful new Machine Learning approach to increase sensitivity
     Title: REFINE Method: Novel Strategy for Signal Enhancement
     Session Title: Artificial Intelligence and Machine/Deep Learning 3
     Location: Poster Section 36 Board 24
     Abstract Number: 4928
     Date/Time: Tuesday April 9, 9:00AM to 12:30PM
     Presenting Author: Michael Wang, PhD

Subject: Promising initial results in breast cancer for screening patients with dense breast tissue
     Title: Improving Cancer Screening Performance for Women with Dense Breast Tissue
     Session Title: Population-Based Screening
     Location: Poster Section 32 Board 13
     Abstract Number: 4796
     Date/Time: Tuesday April 9, 9:00AM to 12:30PM
     Presenting Author: Molly Smith

Subject: Robust performance even when cfDNA inputs decrease
     Title: Optimization of a Liquid Biopsy Assay to Accommodate Low cfDNA Samples and Increase Throughput
     Session Title: Advances in Genomic Sequencing Platforms, Methodologies, and Interpretation 1
     Location: Poster Section 14 Board 11
     Abstract Number: 323
     Date/Time: Sunday April 7, 1:30PM to 5:00PM
     Presenting Author: Michael Salmans, PhD

More information can be found on the AACR meeting website.

About Genece Health

Genece leverages a proprietary liquid biopsy and deep-learning AI technology for early cancer detection. The Company was founded in 2022 through a strategic partnership with GC Genome, the genomics arm of GC Corporation, a leading life sciences company in South Korea. Genece focuses on the acute need for targeted screening tools to support decision-making when a mass or lump is detected through imaging, empowering physicians to make informed decisions and improve care. The Company’s initial applications include high-mortality and women’s health cancers. For more information, visit genecehealth.com or follow Genece on Linkedin.

Investor Contact:

investors@genecehealth.com